| SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus M Dogan, L Kozhaya, L Placek, C Gunter, M Yigit, R Hardy, M Plassmeyer, ... Communications Biology 4 (1), 129, 2021 | 147 | 2021 |
| Engineering human MAIT cells with chimeric antigen receptors for cancer immunotherapy M Dogan, E Karhan, L Kozhaya, L Placek, X Chen, M Yigit, D Unutmaz The Journal of Immunology 209 (8), 1523-1531, 2022 | 28 | 2022 |
| Targeting SARS‐CoV‐2 infection through CAR‐T‐like bispecific T cell engagers incorporating ACE2 M Dogan, L Kozhaya, L Placek, F Karabacak, M Yigit, D Unutmaz Clinical & Translational Immunology 11 (10), e1421, 2022 | 8 | 2022 |
| Mucosal-associated invariant T cells in cancer: dual roles, complex interactions and therapeutic potential M Yigit, OF Basoglu, D Unutmaz Frontiers in Immunology 15, 1369236, 2024 | 2 | 2024 |
| Engineering programmable CAR-T cells with tunable controls as fail-safe mechanisms during cancer immunotherapy M Dogan, L Kozhaya, L Placek, E Karhan, M Yigit, C Mohammed, Q Zhao, ... bioRxiv, 2024.07. 09.602762, 2024 | | 2024 |
| Engineering human Mucosal Associated Invariant T (MAIT) cells with chimeric antigen receptors for cancer immunotherapy1 M Dogan, E Karhan, L Kozhaya, L Placek, X Chen, M Yigit, D Unutmaz bioRxiv, 2022.07. 28.501764, 2022 | | 2022 |
| Targeting SARS-CoV-2 infection through CAR T cells and bispecific T cell engagers M Dogan, L Kozhaya, L Placek, F Karabacak, M Yigit, D Unutmaz bioRxiv, 2022 | | 2022 |
